Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Aleixo Muise Laboratory, |
RCV004562229 | SCV005088107 | pathogenic | Gastrointestinal defects and immunodeficiency syndrome 1 | 2024-07-05 | criteria provided, single submitter | research | PS1;PM2;PM3;PP3;PP4 |
Fulgent Genetics, |
RCV004562229 | SCV005661077 | pathogenic | Gastrointestinal defects and immunodeficiency syndrome 1 | 2024-03-26 | criteria provided, single submitter | clinical testing | |
OMIM | RCV004562229 | SCV000071330 | pathogenic | Gastrointestinal defects and immunodeficiency syndrome 1 | 2013-09-01 | no assertion criteria provided | literature only | |
Prevention |
RCV003415786 | SCV004115431 | pathogenic | TTC7A-related disorder | 2024-05-04 | no assertion criteria provided | clinical testing | The TTC7A c.1001+3_1001+6delAAGT variant is predicted to result in an intronic deletion. This variant was reported in the homozygous and compound heterozygous state with a second pathogenic variant in multiple individuals with multiple intestinal atresia (also described as c.53344_53347delAAGT or c.1000delAAGT; Samuels et al. 2013. PubMed ID: 23423984; Chen et al. 2013. PubMed ID: 23830146; Table E1, Stray-Pedersen et al. 2016. PubMed ID: 27577878; Mandiá et al. 2018. PubMed ID: 29879038). This variant is reported in 0.0079% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. |